1 / 27

CLINICAL PROTOCOL DEVELOPMENT

What's The Question?. What is the study hypothesis?. What's The Question?. What's the outcome?What's the intervention?When and for how long?For whom? How many participants are needed?How can we optimize potential benefit (and what we learn) while minimizing potential harm? . Answering the Question.

Jims
Download Presentation

CLINICAL PROTOCOL DEVELOPMENT

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


    1. CLINICAL PROTOCOL DEVELOPMENT

    3. What’s The Question? What’s the outcome? What’s the intervention? When and for how long? For whom? How many participants are needed? How can we optimize potential benefit (and what we learn) while minimizing potential harm?

    4. Answering the Question Response variable selection and measurement Defining the intervention Study design Eligibility criteria Sample size estimate Patient management procedures Monitoring for safety and benefit Data analysis approaches

    5. Response Variable Selection “Dose ranging” Biologic activity Biomarker Understand mechanism Surrogate outcome Toxicity Condition/vector/gene interaction Feasibility for larger study Clinical outcome

    6. Response Variable Criteria Well defined Stable Reproducible Unbiased Ascertainable in all participants Adequately address study hypothesis

    7. Defining the Intervention Dose/dosing schedule Vector Route of delivery Method of preparation

    8. Study Design Uncontrolled Controlled Before/after Historical Concurrent, not randomized Randomized

    9. Comparing Treatments

    10. Non-randomized Trials May Be Appropriate

    11. Advantages of Randomized Control Clinical Trial 1. Randomization "tends" to produce comparable groups 2. Randomization produces valid statistical tests

    12. Disadvantages of Randomized Control Clinical Trial 1. Generalizable Results? Participants studied may not represent general study population. 2. Recruitment Hard 3. Acceptability of Randomization Process Some physicians will refuse Some participants will refuse 4. Administrative Complexity

    13. Study Population Subset of the general population determined by the eligibility criteria General population Eligibility criteria Study population Enrollment Study sample Observed

    14. Eligibility Criteria State in advance Consider Potential for effect of intervention Ability to detect that effect Safety Ability for true informed consent

    15. Sample Size (1) The study is an experiment in people Need enough participants to answer the question Should not enroll more than needed to answer the question Sample size is an estimate, using guidelines and assumptions

    16. Sample Size (2) Approaches for early phase studies Dose escalation schemes Decision that intervention is unlikely to be effective in ?x% of participants Decision that intervention could be effective in ?x% of participants Standard ways of estimating for phase III

    17. Sample Size (3) Assumptions depend on Nature of condition Desired precision of answer Availability of alternative treatments Knowledge of intervention being studied Availability of participants

    18. Regular Follow-up Routine Procedures (report forms) Interviews Examinations Laboratory Tests Adverse Event Detection/Reporting Quality Assurance

    19. Contingency Plans Patient management Evaluation and reporting to all relevant persons and groups Data monitoring plans Protocol amendment or study termination

    20. Data Analysis (1) Occurrence of event Time to event Mean level of response Duration of response

    21. Data Analysis (2) Intention-to-treat Explanatory Subgroups Adjusted vs. Unadjusted

    22. Data Analysis (3) Specify in advance Primary Secondary Other Statistical approach Exploratory

    23. Clinical Protocol (1) Background/Justification --Where we are in the field --What the study will add that is important Objectives --Primary hypothesis --Secondary hypotheses --Other

    24. Clinical Protocol (2) Study Design and Methods --Type of study, comparison --Inclusion and exclusion criteria --Description of intervention (what, how) --Concomitant therapy --Examination procedures (baseline, follow-up, outcome assessment) --Intervention assignment procedure

    25. Clinical Protocol (3) Monitoring and Management --Data and safety monitoring --Adverse event assessment, reporting --Contingency procedures --Withdrawal criteria

    26. Clinical Protocol (4) Statistics --Sample size --Stopping guidelines --Analysis plans Participant protection issues

    27. Summary Protocol lays out who, what, why, when, where, how Safeguards participants Safeguards study integrity Midcourse changes are often appropriate (even necessary)

More Related